
News|Articles|September 1, 2003
Treatment for male pattern baldness delays prostate cancer
Finasteride (Propecia, Merck), an inhibitor of 5a-reductase, prevents or delays the appearance of prostate cancer by 24.8% (P<.001), according to researchers from the University of Texas Health Science Center, San Antonio, Texas.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
4
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
5


























